Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tilray BrandsTLRY -2.76%51 EV-to-EBIT is -0.38 as of Jul. 25, 2026. GuruFocus rates TLRY with a GF Score™ of 51/100 and a GF Value™ of $12.50 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Tilray Brands ranks worse than 144927.39% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Tilray Brands's Enterprise Value for the quarter that ended in Feb. 2026 was $980.1 Mil.
Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,424.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tilray Brands EV-to-EBIT Related Terms
Tilray Brands EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Tilray Brands's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tilray Brands EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Tilray Brands's EV-to-EBIT falls into.
Tilray Brands's current Enterprise Value is $544.4 Mil.
Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,424.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tilray Brands (TLRY) has a EV-to-EBIT of -0.38 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tilray Brands and its competitors. According to the industry distribution chart, Tilray Brands ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Tilray Brands' EV-to-EBIT too high?
Tilray Brands' current EV-to-EBIT is -0.38. Based on the distribution chart, Tilray Brands ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tilray Brands has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tilray Brands' EV-to-EBIT compare to AQST and EOLS?
According to the Drug Manufacturers industry distribution chart, Tilray Brands ranks #999999 out of 690 companies for EV-to-EBIT. This places Tilray Brands in the lower half of its industry. The industry median EV-to-EBIT is 15.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Tilray Brands and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tilray Brands's current EV-to-EBIT is -0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tilray Brands stock overvalued right now?
Based on GuruFocus' analysis, Tilray Brands (TLRY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.50, compared to a current price of $3.88 — trading 69% below its estimated fair value. The current EV-to-EBIT is -0.38. Tilray Brands' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Tilray Brands (TLRY), the current EV-to-EBIT is -0.38 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tilray Brands (TLRY) Overvalued in 2026?
Based on GuruFocus' analysis, Tilray Brands stock appears to be undervalued.
The current stock price of $3.88 is trading 69% below its estimated GF Value™ of $12.50.
GuruFocus considers Tilray Brands to be Possible Value Trap.
Key valuation signals for TLRY:
EV-to-EBIT: -0.38
GF Value™: $12.50 vs. price of $3.88 (69% below fair value)
No single metric tells the full story. See the TLRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
51GF Score
Get the complete analysis for TLRY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLRY has been successfully added to your 
